The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | AVENuE: avelumab for classical Hodgkin lymphoma
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares his insights into the AVENuE trial (NCT03617666), a Phase II investigator – initiated study in the UK. Dr Collins discusses the structure of the trial and its potential use in the treatment of classical Hodgkin lymphoma. Dr Collins explains the various stages of the trial, including the use of avelumab, a PD-L1 inhibitor, followed by various chemotherapy treatment options depending on patient response and PET scan results. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Disclosures
Roche, Takeda, Gilead, Novartis, BMS, Pfizer, ADC Therapeutics, Incyte, Beigene, Daiichi Sankyo.
